Our latest articles
The Belgian group has bolstered its epilepsy offering with a $1.9bn move on Zogenix.
Almost in stealth mode, Cytokinetics has pressed on with the heart failure project, which now awaits a key regulatory catalyst.
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
How long can it be before the total breaches $10bn?
Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex’s monopoly.
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.